Table 2.

Results from generalized linear mixed models evaluating opiate use along with changes in craving and depressive symptoms assessed on the day of the first dose of buprenorphine and 1-, 3-, 7-, 9-, and 11-weeks after initiating buprenorphine treatment.

	Positive Opiate Tests			Craving			Depression
	B	SE	p	B	SE	p	B	SE	p
Base model terms
(Intercept)	-3.50	2.32	0.13	2.13	0.92	0.02	3.97	5.95	0.51
Linear Time	-0.62	0.21	0.00	-0.16	0.02	0.00	-3.01	0.47	0.00
Quadratic Time	0.05	0.02	0.01	--	--	--	0.23	0.04	0.00
Planned Baseline Covariates
Age	0.01	0.03	0.78	-0.01	0.29	0.91	0.04	0.09	0.66
Gender	0.06	0.77	0.98	-0.03	0.01	0.49	-0.81	1.83	0.66
Opiate use days	4.92	2.37	0.04	2.22	0.96	0.01	6.64	5.30	0.22
Craving	0.03	0.39	0.94	0.12	0.15	0.41	-0.30	0.95	0.75
Beck Depression	-0.06	0.04	0.12	-0.04	0.01	0.02	0.31	0.09	0.00
Treatment Effect
Escitalopram vs. Placebo	-0.02	0.74	0.98	0.27	0.28	0.34	4.77	1.76	0.01
Behavioral Stress Challenge
PASAT	-0.004	0.002	0.04	0.000	0.001	0.90	0.006	0.005	0.24